Is the cancer survival improvement in European and American adolescent and young adults still lagging behind that in children?


Journal

Pediatric blood & cancer
ISSN: 1545-5017
Titre abrégé: Pediatr Blood Cancer
Pays: United States
ID NLM: 101186624

Informations de publication

Date de publication:
01 2019
Historique:
received: 13 03 2018
revised: 23 07 2018
accepted: 24 07 2018
pubmed: 21 8 2018
medline: 23 10 2019
entrez: 21 8 2018
Statut: ppublish

Résumé

Improvements during 1978 to 2006 in the 5-year survival rate of adolescents and young adults (AYAs, age 15-39) and children with cancers common to both age groups were evaluated for 1978 to 2006 in Europe and the USA. AYAs had absolute survival increases of 25% and 15% in Europe and the USA, respectively, but in both cases, AYA 5-year survival was, as of 2006, 4% lower than those in children. Acute lymphoblastic leukemia (ALL) explained most of the survival difference between AYAs and children on both the continents. In the USA, 20- to 39-year-olds with ALL have had less survival improvement than those in Europe.

Identifiants

pubmed: 30124231
doi: 10.1002/pbc.27407
doi:

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

e27407

Informations de copyright

© 2018 Wiley Periodicals, Inc.

Auteurs

Annalisa Trama (A)

Evaluative Epidemiology Unit, Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Milan, Italy.

Alice Bernasconi (A)

Evaluative Epidemiology Unit, Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Milan, Italy.

Martin G McCabe (MG)

Institute of Cancer Sciences, University of Manchester, Manchester, UK.

Marcela Guevara (M)

Public Health Institute of Navarra, IdiSNA, Pamplona, Spain.
CIBER Epidemiología y Salud Pública (CIBERESP), Madrid, Spain.

Gemma Gatta (G)

Evaluative Epidemiology Unit, Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Milan, Italy.

Laura Botta (L)

Evaluative Epidemiology Unit, Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Milan, Italy.
Evaluative Epidemiology Unit, Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Milan, Italy.

Lynn Ries (L)

RiesSearch LLC, Rockville, Maryland.

Archie Bleyer (A)

Oregon Health and Science University, Portland, Oregon.
University of Texas Medical School at Houston, Houston, Texas.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH